NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

NASDAQ / LIVE COMPANY INTELLIGENCE

Eikon Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKEREIKN
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / EIKN COVERAGE

What’s moving Eikon Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

The story matters when it changes Eikon Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Eikon Therapeutics, Inc.: Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Therapeutics, Inc.: Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

The story matters when it changes Eikon Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?

Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?

Investors are testing whether Eikon Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Eikon Therapeutics, Inc.: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

Eikon Therapeutics, Inc.: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

The story matters when it changes Eikon Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Eikon Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell

Eikon Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell

Investors are testing whether Eikon Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest EIKN filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-13 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-11 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-03-30 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-14 · Period 2026-08-13SEC ↗8-KMaterial company eventFiled 2026-08-13 · Period 2026-08-13SEC ↗8-KMaterial company eventFiled 2026-08-03 · Period 2026-07-31SEC ↗4Official SEC filingFiled 2026-09-08 · Period 2026-09-03SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-08-06SEC ↗
EARNINGS / QUARTERLY TRACKER

Eikon Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.